

MARKSANS PHARMA LIMITED

Read Office: 11th Floor, Lotus Business Park Off. New Link Road, Andheri (West), Mumbai-400053

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2013

PART 1

(₹ in Lakhs)

Sr. No.	PARTICULARS	3 MONTHS ENDED				ended Previous Year
		30.9.2013 (UNAUDITED)	30.06.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)	30.9.2013 (UNAUDITED)	
1	Income					
a)	Net Sales/ Income from Operations (Net of excise duty)	7,851.37	7,202.09	4,672.64	15,053.45	19,229.70
b)	Other Operating Income	-	270.38	356.17	270.38	417.18
	Total Income from operations (net)	7,851.37	7,472.47	5,028.81	15,323.83	19,646.88
2	Expenses					
a)	Cost of Material Consumed	3,245.68	2,463.49	1,914.72	5,709.17	3,383.67
b)	Purchase of Stock - in- trade	674.01	782.11	341.82	1,456.12	654.74
c)	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(45.23)	155.79	(0.32)	110.56	(2.81)
d)	Employee benefits expense	478.42	468.06	352.38	946.48	705.80
e)	Depreciation and amortisation expense	223.97	220.46	218.06	444.43	432.63
f)	Other expenses	1,047.71	908.86	536.20	1,956.57	3,741.59
	Total Expenses	5,624.56	4,998.77	3,362.86	10,623.33	15,673.14
3	Profit/(Loss) from operations before other Income, finance costs and exceptional items (1-2)	2,226.81	2,473.70	1,665.95	4,700.50	(63.54)
4	Other Income	-	-	-	-	-
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	2,226.81	2,473.70	1,665.95	4,700.50	(63.54)
6	Finance cost	254.12	752.91	226.13	1,007.03	469.47
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	1,972.69	1,720.79	1,439.82	3,693.47	(533.01)
8	Exceptional items	-	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	1,972.69	1,720.79	1,439.82	3,693.47	(533.01)
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	193.04	41.96	1,439.82	236.00	(997.77)
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	1,779.65	1,678.83	1,439.82	3,458.47	(533.01)
12	Less: Extraordinary item	-	-	-	-	-
13	Net Profit/ (Loss) for the period (11-12)	1,779.65	1,678.83	1,439.82	3,458.47	(533.01)
14	Paid up Equity Share Capital (Face Value Re. 1 each)	3,853.07	3,853.07	3,678.07	3,853.07	3,853.07
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	-
16 a)	Earnings Per Share (before extraordinary items Rs.) - Basic	0.46	0.44	0.39	0.90	(0.14)
	- Diluted	0.46	0.44	0.37	0.90	(0.14)
b)	Earnings Per Share(after extraordinary items- Rs.) - Basic	0.46	0.44	0.39	0.90	(0.14)
	- Diluted	0.46	0.44	0.37	0.90	(0.14)
PART 2						
A PARTICULARS OF SHAREHOLDING						
1	Public Shareholding:					
	- Number of Shares	187,815,471	187,999,472	189,824,114	187,815,471	188,634,244
	- Percentage of Holding	48.75%	48.79%	51.61%	48.75%	48.96%
2	Promoters and Promoter group Shareholdings	197,491,733	197,307,732	177,983,090	197,491,733	196,672,960
a)	Pledged/Encumbered					
	- Number of Shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	N/A
b)	Non-encumbered					
	- Number of Shares	197,491,733	197,307,732	177,983,090	197,491,733	196,672,960
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	51.25%	51.21%	48.39%	51.25%	51.04%



B/ INVESTOR COMPLAINTS	3 MONTHS ENDED
Pending at the beginning of the quarter	30.9.2013
Received during the quarter	Nil
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	2
	Nil

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31.10.2013.
- The Company has published its consolidated financial statements separately. On consolidated basis, it has achieved revenue of ₹ 30,513.13 Lacs and PAT of ₹ 3,879.40 Lacs for the half year ended 30.09.2013.
- The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- Previous year's figures have been re-grouped/re-classified, whenever necessary, so as to make them comparable with the current year's figures.
- Statement of Assets and Liabilities:

Particulars	As at	
	30.09.2013	31.03.2013
	UNAUDITED	AUDITED
A		
EQUITY AND LIABILITIES		
1		
(a) Shareholders' funds		
(b) Share capital	5,203.07	5,203.07
(c) Reserves and surplus	9,253.03	5,794.56
(c) Money received against share warrants	-	-
Sub-total-Shareholders' funds	14,456.10	10,997.63
2		
(a) Non-current liabilities		
(b) Long-term borrowings	654.64	787.88
(b) Deferred tax liabilities (Net)	222.13	222.13
Sub-total - Non-current liabilities	876.77	1,009.81
3		
(a) Current liabilities		
(b) Short-term borrowings	7,493.50	7,531.23
(b) Trade payables	3,632.64	2,985.94
(c) Other current liabilities	4,624.30	7,505.16
(d) Short-term provisions	398.73	994.99
Sub-total-Current liabilities	18,087.17	19,017.32
TOTAL-EQUITY AND LIABILITIES	31,420.04	31,024.76
B		
ASSETS		
1		
(a) Non-current assets		
(a) Fixed assets	7,004.82	7,285.45
(b) Non-current Investments	6,761.64	6,761.64
(c) Long-term loans and advances	119.25	120.22
Sub-total - Non-current assets	13,885.71	14,167.31
2		
(a) Current assets		
(a) Inventories	5,360.18	5,131.76
(b) Trade receivables	10,817.17	9,141.88
(c) Cash and cash equivalents	642.85	41.30
(d) Short-term loans and advances	714.13	2,542.51
(e) Other current assets- Miscellaneous expenditure	-	-
Sub-total- Current assets	17,534.33	16,857.45
TOTAL ASSETS	31,420.04	31,024.76

₹ In Lakhs

For MARKSANS PHARMA LIMITED

MARK SILDANHA
Managing Director



Place: Mumbai.
Date: 31.10.2013
www.marksanspharma.com

MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri (West), Mumbai-400053
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2013

PART 1

Sr. No.	PARTICULARS	3 MONTHS ENDED				6 MONTHS ENDED		Previous Year ended 31.03.2013 (AUDITED)
		30.9.2013 (UNAUDITED)	30.06.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)	30.9.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)		
1	Income							
a-	Net Sales/ Income from Operations (Net of excise duty)	16,135.40	14,103.11	10,552.64	30,238.51	20,016.86	43,842.24	
b-	Other Operating Income	2.45	272.17	365.41	274.62	437.51	439.54	
	Total Income from operations (net)	16,137.85	14,375.28	10,918.05	30,513.13	20,454.37	44,281.78	
2	Expenses							
a)	Cost of Material Consumed	5,870.39	4,313.89	3,630.40	10,184.28	6,650.86	13,592.88	
b)	Purchase of Stock - in-trade	3,399.51	3,421.11	2,364.05	6,820.62	4,767.48	10,478.15	
c)	Changes in Inventories of finished goods, work-in-progress and stock - in-trade	(45.23)	155.79	(0.32)	110.56	(2.81)	1,215.43	
d)	Employee benefits expense	1,853.41	1,518.01	1,350.29	3,371.41	2,579.60	5,591.25	
e)	Depreciation and amortisation expense	317.50	320.54	498.77	638.04	751.52	1,564.99	
f)	Other expenses	2,094.22	1,787.61	1,273.80	3,881.83	5,185.16	6,024.71	
	Total Expenses	13,459.80	11,516.95	9,116.99	25,006.74	19,931.81	38,467.41	
3	Profit/(Loss) from Operations before other income, finance costs and exceptional items (1-2)	2,648.05	2,858.33	1,801.06	5,506.39	522.56	5,814.37	
4	Other Income	-	-	-	-	-	-	
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	2,648.05	2,858.33	1,801.06	5,506.39	522.56	5,814.37	
6	Finance cost	399.41	859.14	341.29	1,258.54	700.72	1,459.64	
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	2,248.64	1,999.19	1,459.77	4,247.85	(178.16)	4,354.73	
8	Exceptional items	-	-	-	-	-	-	
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	2,248.64	1,999.19	1,459.77	4,247.85	(178.16)	4,354.73	
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	195.51	82.78	1,459.77	278.29	-	(527.89)	
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	2,053.13	1,916.41	-	3,969.56	(178.16)	4,882.62	
12	Less: Extraordinary item	-	-	-	-	-	-	
13	Net Profit/ (Loss) for the period (11-12)	2,053.13	1,916.41	1,459.77	3,969.56	(178.16)	4,882.62	
14	Share of Profit/(Loss) of associates	-	-	-	-	-	-	
15	Minority Interest	52.06	38.10	57.28	90.16	127.01	294.19	
16	Net Profit/(Loss) after taxes, minority interest and share of associates(13-14-15)	2,001.07	1,878.31	1,402.49	3,879.40	(305.17)	4,588.43	
17	Paid up Equity Share Capital (Face Value Re.1 each)	3,853.07	3,853.07	3,678.07	3,853.07	3,678.07	3,853.07	
18	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	-	-	
19	a) Earnings Per Share (before extraordinary items, Rs.)- Basic	0.53	0.50	0.40	1.03	(0.05)	3,444.80	
	Diluted	0.53	0.50	0.38	1.03	(0.05)	1.27	
	b) Earnings Per Share(after extraordinary items- Rs.)- Basic	0.52	0.49	0.38	1.01	(0.06)	1.19	
	Diluted	0.52	0.49	0.36	1.01	(0.08)	1.19	
PART 2								
A PARTICULARS OF SHAREHOLDING								
1	Public Shareholding:							
	- Number of Shares	187,815,471	187,999,472	189,824,114	187,815,471	189,824,114	188,634,244	
	- Percentage of Holding	48.75%	48.79%	51.61%	48.75%	51.61%	48.96%	
2	Promoters and Promoter group Shareholdings	197,491,733	197,307,732	177,983,090	197,491,733	177,983,090	196,672,960	
	a). Pledged/Encumbered							
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A	N.A	N.A	
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A	N.A	N.A	
	b). Non-encumbered							
	- Number of Shares	197,491,733	197,307,732	177,983,090	197,491,733	177,983,090	196,672,960	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total share capital of the Company)	51.25%	51.21%	48.39%	51.25%	48.39%	51.04%	



B/ INVESTOR COMPLAINTS	3 MONTHS ENDED
Pending at the beginning of the quarter	30.9.2013
Received during the quarter	Nil
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	2

PART 3 Standard Information	3 MONTHS ENDED					Previous Year ended
	30.09.2013 (UNAUDITED)	30.06.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)	30.9.2013 (UNAUDITED)	30.9.2012 (UNAUDITED)	
Revenue	7,851.37	7,472.47	5,028.81	15,323.83	8,852.08	19,646.88
Profit Before Tax from Ordinary activities	1,872.88	1,720.79	1,439.82	3,693.47	(533.01)	2,960.50
Profit After Tax from Ordinary activities	1,779.85	1,678.83	1,439.82	3,458.47	(533.01)	3,958.27
Profit After Tax after extraordinary item	1,779.85	1,678.83	1,439.82	3,458.47	(533.01)	3,958.27

- Notes:
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31.10.2013.
 - The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australia Pty Ltd and Marksans Pharma (UK) Limited.
 - The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
 - The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
 - The Company will consider the effect of Deferred Tax Asset/(Liabilities) - AS 22 in the audited accounts at the year end.
 - Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
 - Statement of Assets and Liabilities:

Particulars	As at		31.03.2013	31.03.2013
	30.09.2013	31.03.2013		
A	EQUITY AND LIABILITIES	UNAUDITED	AUDITED	
1	Shareholders' funds	5,203.07	5,203.07	
	(a) Share capital	6,158.81	3,444.80	
	(b) Reserves and surplus			
	(c) Money received against share warrants	11,361.88	8,647.87	
	Sub-total-Shareholders' funds	609.86	699.00	
2	Minority Interest	654.64	787.68	
	(a) Non-current liabilities	270.51	261.64	
	(b) Long-term borrowings	825.15	1,049.32	
	(e) Deferred tax liabilities (Net)			
	Sub-total - Non-current liabilities			
3	Current liabilities	12,070.40	11,378.70	
	(a) Short-term borrowings	6,419.26	5,606.16	
	(b) Trade payables	9,616.67	10,873.44	
	(c) Other current liabilities	2,797.52	1,898.96	
	(d) Short-term provisions	30,903.85	29,728.26	
	Sub-total-Current liabilities	43,800.84	40,124.45	
	TOTAL-EQUITY AND LIABILITIES			
B	ASSETS			
1	Non-current assets	15,222.03	15,452.63	
	(a) Fixed assets	159.00	159.00	
	(b) Goodwill on consolidation	119.25	120.21	
	(c) Non-current Investments	15,500.28	15,731.84	
	(d) Long-term loans and advances			
	Sub-total - Non-current assets			
2	Current assets	10,439.48	7,789.19	
	(a) Inventories	16,203.61	13,131.42	
	(b) Trade receivables	677.47	1,588.00	
	(c) Cash and cash equivalents	890.00	1,904.00	
	(d) Short-term loans and advances			
	(e) Other current assets- Miscellaneous expenditure	28,300.56	24,392.61	
	Sub-total-Current assets	43,800.84	40,124.45	

Place: Mumbai,
Date: 31.10.2013
www.marksanspharma.com

MARKSANS PHARMA LTD.
MUMBAI-53

For **MARKSANS PHARMA LIMITED**
MARK SALDANHA
Managing Director.



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

817, Bldg. No. 3, Navjivan Commercial Premises Co.-op. Soc., Lamington Rd., Mumbai Central (E), Mumbai - 400 008.
☎ : 2309 6121 • Mob. : 98926 40589 • E-mail : ca_mittal@rediffmail.com • nkmittalandassociates@gmail.com

N. K. Mittal
B.Com, FCA, LLB, EMBA


LIMITED REVIEW REPORT FOR THE PERIOD ENDED 30.09.2013

We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 30th September, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. K. MITTAL & ASSOCIATES
Chartered Accountants


N.K.MITTAL
(Proprietor)
M.No.46785
Place: Mumbai
Date: 31.10.2013

